INNOAESTHETICS

INNOAESTHETICS is a Spanish dermocosmetic and aesthetic-medicine laboratory based in Sant Just Desvern, near Barcelona, and operated by the company Laboratorio Innoaesthetics, S.L.U. It develops products for skin professionals — chemical peels, transdermal solutions, injectable hyaluronic acid gels, dermocosmetics and depigmentation treatments — and sells them to dermatologists and aesthetic doctors rather than directly to consumers. The company traces its roots to a Barcelona family pharmacy opened in 1898, and presents itself as a science-led laboratory serving aesthetic professionals worldwide [1][3].

The business remains active. It reports a presence in more than 80 countries through exclusive distributors, launched a notable new product in 2024, and continued publishing professional content into 2025 and 2026.

The laboratory dates its origin to 1898, when Antonio Fita Trías opened the first family pharmacy in Barcelona [3]. The company records that this pharmacy grew into one of the city's most important by 1915. In 1934 his successor, Antoni Fita Ramírez, formally created a laboratory and expanded the family business, developing tailored formulas for doctors.

INNOAESTHETICS describes its history as spanning four generations of the same family. The third generation, Fernando Bouffard Vicente MD, became Medical Director in 1958. In 1992 the fourth generation, Fernando Bouffard Fita Ph.D., took over and steered the firm toward dermatological and aesthetic medicine. (The company's laboratory page refers to him more briefly as "Fernando Bouffard, Ph.D., CEO," while the detailed timeline adds the full name to distinguish him from his same-named predecessor.)

The company's first commercial success came in 1997 with ANESTOP, which it describes as its first topical anaesthetic and first best-seller [3]. Over the following decades the laboratory broadened from individual products into structured professional ranges and training. It founded the Skin Academy Barcelona in 2011 as a professional training initiative, and in 2015 consolidated its various product lines under the single INNOAESTHETICS name while establishing a separate manufacturing unit, EXPERTISSE [3].

A series of launches followed. The MELINE depigmentation line arrived in 2016, described by the company as a range formulated according to the specific type of hyperpigmentation being treated. In 2018 the laboratory introduced its Smart GPS delivery system and the INNO-DERMA EPIGEN line, supported by what the company reports as a five-million-euro expansion. In 2020 it released INNO-CE, a line of injectable hyaluronic acid gels comprising seven CE-marked products.

INNOAESTHETICS is owned and operated by Laboratorio Innoaesthetics, S.L.U., a Spanish company [1]. It has remained under the same family's control across its generations of leadership, and no acquisitions or change of ownership are documented.

The company positions itself as a "model laboratory" in aesthetic medicine and dermocosmetics, and says it works "to design smart and more effective products to prevent and treat all kinds of skin alterations and aesthetic concerns" [2]. Its stated commitments include the well-being of people, ethical business practices and environmental stewardship [2]. The tagline used across its materials is "Innovation from Experience."

Its model is professional rather than retail. The company's consumer-facing range is closed to the public, and its products reach the market through distributors and practitioners; its audience is described in editorial coverage as dermatologists, aesthetic doctors and skincare professionals [7]. Alongside its own brands, the firm runs a contract-manufacturing arm under the EXPERTISSE name, which it says draws on more than 30 years of experience and works with over 150 companies on cosmetic products [5].

The product portfolio centres on injectables, peels, transdermal solutions, dermocosmetics and depigmentation treatments. Recurring active ingredients across its lines include hyaluronic acid, vitamin A and amino-acid peptides that act as precursors to collagen and elastin. The company markets named clinical methods to practitioners — among them the Triple R, VPA, R-Eye, Ultra Hyalurolift and Scars Reverse techniques — most built around non-crosslinked hyaluronic acid.

Its central proprietary technology is Smart GPS, a "Guidance Performance System" the company describes as delivering ingredients to a specific group of cells "where they have the maximum therapeutic effect" [2]. In March 2024 the laboratory introduced INNO-EXOMA EXO-SKIN, which it and trade press described as the first synthetic exosome developed in Europe [8]. The product is built on a proprietary process the company calls NARBEX (Non-Animal Regenerative Bioengineering Exosome); according to its medical director, it assembles essential amino acids into crosslinked peptide fibrils, and each vial is said to contain 200 million exosome-like molecules that are fully synthetic and free of animal and plant origins. According to the same coverage, INNO-EXOMA became one of the brand's top-selling products within less than a year of launch [8].

Mainstream consumer beauty press does not cover INNOAESTHETICS, consistent with its professional-only model. The niche aesthetic-medicine publication Anti Age and Longevity Magazine featured the company in 2025, reporting its 1898 origins, its presence in more than 80 countries, and a claim that the firm ranks among the top three most influential brands in the aesthetic-product sector in China [7].

INNOAESTHETICS is active. It describes itself as having more than 125 years of history in dermocosmetics, dating from its 1898 origin [2], and continues to operate from its Barcelona facility and to distribute internationally. Its most recent visible activity includes the March 2024 INNO-EXOMA launch and professional blog posts dated into 2025 and 2026.